Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 9/20 | 0.38 |
| ▸ | HTR6 | P50406 | 2/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28135474 | 0.98 | SLC6A4 (0.37) | SLC6A4HTR6HTR2CHTR2BGRIA2 | |
| Ethane SCHEMBL28136149 | 0.96 | SLC6A4 (0.37) | SLC6A4HTR6HTR2CHTR2BGRIA2 | |
| SCHEMBL28135432 | 0.83 | GRIA2 (0.32) | SLC6A4HTR6GRIA2 | |
| SCHEMBL16345371 | 0.83 | SLC6A4 (0.36) | SLC6A4HTR6HTR2CHTR2BGRIA2 | |
| SCHEMBL19734402 | 0.77 | SLC6A4 (0.35) | SLC6A4HTR6HTR2CHTR2BGRIA2 | |
| SCHEMBL1602688 | 0.77 | SLC6A4 (0.37) | SLC6A4HTR6HTR2CHTR2BGRIA2 | |
| SCHEMBL9224957 | 0.77 | ALDH1A1 (0.42) | SLC6A4HTR6HTR2CHTR2B | |
| SCHEMBL12648514 | 0.77 | SLC6A4 (0.35) | SLC6A4HTR6HTR2CHTR2BGRIA2 | |
| SCHEMBL19681453 | 0.77 | — | — | |
| SCHEMBL5081325 | 0.74 | ALDH1A1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 455 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119977918-A | Synthesis method of 2-bromomethyl-5-trifluoromethyl furan | 上海高准医药有限公司 | 2025-05-13 | — | — | CN | claimed |
| CN-115785080-B | Uracil parent nucleus compound and preparation method and application thereof | 陕西盘龙药业集团股份有限公司 | 2024-10-11 | — | — | CN | claimed |
| US-20170073351-A1 | ENANTIOMERS OF SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2017-03-16 | — | — | US | claimed |
| EP-2789617-B1 | Method of preparation of Enantiomers of spiro-oxindole compounds | XENON PHARMACEUTICALS INC (CA) | 2016-08-17 | — | — | EP | claimed |
| US-20150025121-A1 | ENANTIOMERS OF SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | PACIRA PHARMACEUTICALS, INC. | 2015-01-22 | — | — | US | claimed |
| EP-2789617-A1 | Method of preparation of Enantiomers of spiro-oxindole compounds | Xenon Pharmaceuticals Inc. (CA) | 2014-10-15 | — | — | EP | claimed |
| US-20130072537-A1 | ENANTIOMERS OF SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2013-03-21 | — | — | US | claimed |
| CN-122036587-A | Zalutst compound and application thereof in inhibiting MLL1-WDR5 interaction | 暨南大学 | 2026-05-15 | — | — | CN | disclosed |
| CN-122010876-A | 2-Methyl-5-trifluoromethyl furan and preparation method thereof | 淄博飞源化工有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-20260070896-A1 | HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2026-03-12 | — | — | US | disclosed |
| US-20250388592-A1 | (AZA)SPIROHEPTANE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | REMYND N.V. (BE) | 2025-12-25 | — | — | US | disclosed |
| US-12404266-B2 | Heterocycle derivatives for treating TRPM3 mediated disorders | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2025-09-02 | — | — | US | disclosed |
| EP-4568968-A1 | (AZA)SPIROHEPTANE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Remynd N.V. (BE) | 2025-06-18 | — | — | EP | disclosed |
| US-5405865-A | Pyrethroid esters | ROUSSEL-UCLAF (FR) | 1995-04-11 | — | — | US | disclosed |
| US-5298507-A | Insecticides | NIHON BAYER AGROCHEM K.K. (JP) | 1994-03-29 | — | — | US | disclosed |
| US-5204360-A | Insecticides | NIHON BAYER AGROCHEM K.K. (JP) | 1993-04-20 | — | — | US | disclosed |
| US-5001138-A | Insecticides | NIHON TOKUSHU NOYAKU SEIZO, K.K. (JP) | 1991-03-19 | — | — | US | disclosed |
| US-4845106-A | INSECTICIDES | NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) | 1989-07-04 | — | — | US | disclosed |
| US-4742060-A | 2-(NITROIMINO)- OR 2-(NITROMETHYLENE)-IMIDAZOLIDINES AS INSECTICIDES | NIHON TOKUSHU NOYAKU SEIZO K. K. (JP) | 1988-05-03 | — | — | US | disclosed |
| EP-0192060-A1 | Heterocyclic compounds | NIHON BAYER AGROCHEM K.K. (JP) | 1986-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12404266-B2 | Heterocycle derivatives for treating TRPM3 mediated disorders | TRPM4, TRPM6, TRPM2 | SLC6A4 670/4885HTR6 288/4885HTR2C 289/4885 |
| US-20170073351-A1 | ENANTIOMERS OF SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | TRPV1, TRPV5, TRPV3 | SLC6A4 168/4885HTR6 452/4885HTR2C 295/4885 |
| US-20130072537-A1 | ENANTIOMERS OF SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | TRPV1, TRPV5, TRPV3 | SLC6A4 168/4885HTR6 452/4885HTR2C 295/4885 |
| US-20250388592-A1 | (AZA)SPIROHEPTANE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | SNCA, CHRNA6, CHRNA5 | SLC6A4 338/4885HTR6 148/4885HTR2C 218/4885 |
| US-20260070896-A1 | HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | TRPM6, TRPV3, TRPM2 | SLC6A4 549/4885HTR6 270/4885HTR2C 245/4885 |
| US-20150025121-A1 | ENANTIOMERS OF SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | TRPV1, TRPV5, TRPV3 | SLC6A4 168/4885HTR6 452/4885HTR2C 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.